# CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

> **NCT03774654** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 13 (actual)

## Conditions studied

- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Small Lymphocytic Lymphoma
- Relapsed Adult ALL
- Relapsed CLL
- Relapsed Non Hodgkin Lymphoma

## Interventions

- **GENETIC:** CD19.CAR-aNKT cells

## Key facts

- **NCT ID:** NCT03774654
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-04-14
- **Primary completion:** 2025-06-05
- **Final completion:** 2040-05-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03774654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03774654, "CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03774654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*